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Abstract 
The prevalence of asthma, and the morbidity, adverse events, mortality and healthcare utilisation of 
asthmatic patients vary widely among racial/ethnic and other socio-demographic groups. Debates over 
the meanings of race and ethnicity and the strategic need to resolve health inequalities have prompted 
extensive recommendations for reporting and analyzing racial/ethnic and demographic information in 
clinical trials. We conducted a systematic review to determine the extent to which race/ethnicity, 
socioeconomic status and other demographic variables are analyzed and reported in publications from 
randomized controlled trials of asthma interventions. Randomized controlled trials of inhaled 
corticosteroids and long-acting b-agonists in asthmatic patients were identified by systematically 
searching 12 electronic bibliographic databases. We identified peer-reviewed papers reporting 87 
relevant trials published during 1985–2006, from which we extracted data on patients’ race/ethnicity, 
ancestry, gender, socio-economic variables and geographical attributes. The proportion of the papers 
reporting the race/ ethnicity of their participants was lower than would be expected by chance and has 
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recently declined. None of the papers included race/ethnicity or gender in statistical analyses or 
reported socio-economic variables, ancestry, or genetic data for their participants, and few discussed 
the generalizability of their findings. The frequency of reporting race/ethnicity was statistically 
significantly lower in trials conducted in the UK than in the US, but 23 of the 87 papers did not 
identify countries. Despite extensive recommendations in the literature, guidance from health agencies 
on analyzing and reporting demographic data in clinical trials still appears inconsistent and vague. 
There remains a need to improve guidance on the representation and analysis of minority populations 
in asthma clinical trials, in order to encourage transparent reporting of population selection, analysis 
approaches, and trial generalizability. To assist this process, asthma clinical trials should be based on 
clear hypotheses that link both to existing demographic evidence and to demographic healthcare goals. 
 
Keywords: Ethnic groups; Health status disparities; Minority health; Pharmacogenetics; Socio-
economic factors; Information dissemination; Systematic review 
 
Introduction 
The prevalence of asthma, and asthma-related morbidity, mortality and hospitalization rates are well-
known to differ between population groups that have different ancestral, geographical, and/or cultural 
backgrounds, often referred to as ‘racial’, ‘ethnic’ or ‘racial/ ethnic’ groups (130 examples from 86 
publications are given in Supplementary Table S1).There is extensive evidence that such racial/ 
ethnic differences in asthma may be confounded with, interact with, or serve as a proxy for effects of 
physiological variables such as lung function, and socio-economic variables such as income, 
education, exposure to pollutants, exposure and sensitization to allergens, and access to healthcare (72 
examples from 42 publications are given in Supplementary Table S2). Asthma severity has been 
linked, for example, with social factors that differ among racial/ethnic groups, including 
neighbourhood violence (Tonorezos et al., 2008) and patterns of communication between doctors and 
patients (Diette & Rand, 2007). Interaction ofmany biological, social and environmental factors can 
influence the treatment received by asthma patients and their adherence to it (Shanawani, 2006). The 
prevalence of asthma and the timing of asthma onset are influenced by patterns of migration which in 
turn differ among racial/ethnic groups. For example, immigrants often have lower prevalence of 
asthma than indigenous populations (Kuehni, Strippoli, Low, & Silverman, 2007; Migliore et al., 
2007; Netuveli et al., 2005), and asthma prevalence varies with age at migration (Kuehni et al., 2007), 
place of origin (Holguin et al., 2005; Tedeschi, Barcella, Bo, & Miadonna, 2003), and duration of 
residence at the destination (Leung, Carlin, Burdon, & Czarny,1994;Migliore et al., 2007). Asthma 
incidence, prevalence and risk of exacerbations also vary with age and gender, being higher in 
boys than girls before puberty and then, in adolescents and adults, higher in women than men 
(Johnston & Sears, 2006). Gender differences in the incidence and prevalence of asthma have been 
documented in publications, surveys and databases for several decades (Almqvist, Worm, & Leynaert, 
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2008), although there appears to have been limited public awareness of this (Jensen-Jarolim & 
Untersmayr, 2008).Recent studies have showngender differences in the efficacy of some asthma drugs 
(Johnston et al., 2007; Szefler et al., 2005) and in the risks of adverse events (Ishizuka et al., 2007), 
suggesting that effects of gender should be considered in asthma clinical studies (de Benedictis, 
Baraldi, & Boner, 2008).  
 
Studies of genetic polymorphisms have highlighted the potential value of reporting genetic 
information for populations in clinical trials (Choudhry et al., 2005; Salari et al., 2005). Several gene 
polymorphisms are relevant in asthma patients as they influence responses to b-agonists, 
glucocorticosteroids and leukotriene modifier drugs, which are the three main classes of asthma 
medication (Sayers & Hall, 2007). Polymorphism in the b2-adrenergic receptor gene (ADRB2) differs 
between African American, Caucasian and Chinese populations (Xie et al., 1999) and other 
racial/ethnic groups (Maxwell et al., 2005; Munakata et al., 2006), and has been related to variation in 
patients’ responsiveness to long-acting b-agonists (Israel et al., 2004; Wechsler et al., 2006), short-
acting b-agonists (Hall & Sayers, 2007; Israel et al., 2000), and the frequency of asthma exacerbations 
(Taylor et al., 2000). Racial/ethnic differences have also been observed in the elimination of the long-
acting b-agonist bambuterol (Koysooko et al., 1987) and would be expected in the clearance of 
inhaled corticosteroids such as budesonide, ciclesonide and fluticasone. These drugs are metabolised 
in the liver and gut by the cytochrome P450 enzyme CYP3A4 (Nave, Fisher, & McCracken, in press; 
Pearce, Leeder, & Kearns, 2006; Peet, Enos, Nave, Zech, & Hall, 2005), whose activity varies 
threefold between some racial/ethnic groups (Dorne, 2007). Such genetic variation in 
pharmacokinetics raises the prospect of optimising asthma management for efficacy and safety using 
pharmacogenetic approaches, but there is a shortage of relevant studies (Hall & Sayers, 2007).  
 
The relative importance of and interactions among race/ethnicity, socio-economic status and genetics 
for asthma is the subject of considerable debate (e.g., Apter, 2006; Cooper, 2003; Cooper, Kaufman, 
& Ward, 2003). The latest guidelines from the Global Strategy for Asthma Management and 
Prevention (Bateman et al., 2008) acknowledge, somewhat simplistically, that the apparent ‘racial’ 
and ‘ethnic’ differences in the prevalence of asthma reflect ‘underlying genetic variances with a 
significant overlay of socio-economic and environmental factors’. It is clear that research into asthma 
should take these population differences into consideration but there has been considerable confusion, 
inconsistency and disagreement over the meaning and appropriateness of terms such as ‘race’, 
‘ethnicity’ and ‘race/ethnicity’ (Smart, Tutton, Martin, Ellison, & Ashcroft, 2008). The concept of 
‘race’ in humans has been discredited by the American Anthropological Association (AAA) and 
others as a social construct that has limited biological meaning (Agyemang, Bhopal, & Bruijnzeels, 
2005; American Anthropological Association, 1997, Anonymous, 2000). Although ‘ethnicity’ is 
inconsistently defined (Anonymous, 2000; Collins, 2004), it usually avoids the discredited notion of 
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human sub-species and the potential for pejorative racist interpretation that has been associated with 
the term ‘race’ (Huth, 1995; Witzig, 1996). ‘Ethnicity’ usually implies shared origins, a shared social 
background, and/or shared social culture and traditions, including language and religion (Agyemang 
et al., 2005; Bhopal, 2004; Senior & Bhopal, 1994; Witzig, 1996). The AAA proposed the term 
‘race/ethnicity’ in 1997 as a means to facilitate gradual elimination of ‘race’ from the US population 
census (American Anthropological Association, 1997) and ‘race/ethnicity’ has since been widely 
adopted (Bhopal, 2004). Here, we use ‘race/ethnicity’ to refer broadly to any variables that might be 
classed as ‘racial’ or ‘ethnic’, as defined by Bhopal (2004). 
 
There has been extensive criticism of the use in medical research of racial/ethnic descriptions such as 
Asian (Bhopal, Phillimore, & Kohli, 1991), Black (Agyemang et al., 2005), Caucasian (Bhopal & 
Donaldson, 1998), and Latino (Gonza´ lez Buchard et al., 2005) because differences in ancestry and 
migration which might have clinical relevance cannot be resolved at these very broad, usually 
undefined, classes. Others, however, have argued that the use of broad racial/ethnic categories may 
have some merit as proxy variables that, in the absence of more refined technology, may encode 
important information as a result of their role in social stratification (Cohn, 2006; Kaufman & Cooper, 
2001). Further confusion about the value of racial/ethnic groups has been caused by a general failure 
to clearly define such groups, inconsistent interpretation of the same concept by different people, 
uncertainty about the comparability of self-assigned and independently assigned racial/ethnic status, 
and an increase in the number of people with multi-ethnic backgrounds for whom no clear 
classification system exists (Witzig, 1996). These difficulties with racial/ethnic classifications have 
led to numerous recommendations in the medical literature that broad racial/ethnic classes such as 
Asian, Black, Caucasian, Hispanic, Latino, or White should be abandoned in favour of, or at least 
supplemented by, more precise demographic information including ancestry, migration history, 
culture and socio-economic variables (e.g., inter alia, Agyemang et al., 2005; Anonymous, 1996; 
Bhopal, 2004; Bhopal & Donaldson, 1998; Coons, 2006; Huth, 1995; International Committee 
of Medical Journal Editors, 1997; Kaplan & Bennett, 2003; Winker, 2004). Despite these 
recommendations, broad racial/ethnic classifications continue in clinical research (Schwartz, 2001) 
and in epidemiology and public health (Agyemang, 2006). 
 
Asthma research studies need to consider the importance of population differences in asthma 
morbidity, mortality, responses to management, adverse events, access to healthcare, and 
opportunities for pharmacogenetic therapy, whilst taking into account the difficulties of recruiting, 
including and describing relevant population groups in clinical trials. The representation of 
racial/ethnic minorities in clinical trials is an important component of strategies for reducing 
inequalities in healthcare (Committee on Understanding and Eliminating Racial and Ethnic Disparities 
in Health Care, 2003), and a recognised aim of health agencies including the US National Institutes of 
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Health (National Institutes of Health, 2004) and the UK National Health Service (Hussain-Gambles, 
Atkin, & Leese, 2004). Our objective was to clarify the extent to which randomized controlled clinical 
trials of inhaled asthma interventions consider the ancestry, genetic profiles, geography, and socio-
economic status of their populations for establishing the generalizability of the trials (i.e. to which 
populations their results are applicable) (Hussain-Gambles et al., 2004), for providing patient-centred 
clinical guidance, and for supporting pharmacogenetic developments in asthma management. As 
gender differences in asthma have recently attracted renewed interest (Almqvist et al., 2008; de 
Benedictis et al., 2008; Jensen-Jarolim & Untersmayr, 2008), we also sought to clarify the extent to 
which gender was reported and analyzed in the asthma clinical trials. 
 
Methods 
Information was obtained from two peer-reviewed systematic reviews of randomized controlled trials 
which evaluated the clinical efficacy and safety of inhaled corticosteroids and long-acting beta-
agonists for asthma treatment in adults (Shepherd et al., 2008) and children (Main et al., 2008). The 
reviews were conducted to inform clinical guidance on asthma management that were being 
updated by the UK National Institute for Health and Clinical Excellence (UK National Institute for 
Health and Clinical Excellence, 2008a, 2008b). The systematic reviewwe report here is a secondary 
extraction of data on race/ethnicity and other demographic variables from the papers that were 
included in these primary reviews. Inclusion criteria for the primary systematic reviews were: 
populations: patients of any age, gender, or nationality with chronic asthma of any severity, but 
excluding those with chronic obstructive pulmonary disease and other respiratory co-morbidities. 
Interventions: five inhaled corticosteroids and two combination drugs (inhaled corticosteroid plus 
long-acting b-agonist) (Main et al., 2008; Shepherd et al., 2008), compared head-to-head in any 
combination or against a placebo, at any of their approved doses, with a minimum intervention 
duration of four weeks. Design: randomized controlled trials. Outcomes: trials were included if they 
reported quantitative data for at least one of the following outcomes: forced expiratory volume in one 
second; am peak expiratory flow; pm peak expiratory flow; nocturnal awakening; symptom-free days; 
symptom-free nights; symptom scores; health-related quality of life scores; rescue medication use; 
exacerbations; adverse events. A search strategy common to both reviews was used to identify 
relevant studies (Supplementary Table S3). Twelve electronic bibliographic databases were searched 
during January to March 2006, with searches updated (re-run) in September 2006 (Supplementary 
Table S3). Further details of the reviews are given in the published reports (Main et al., 2008; 
Shepherd et al., 2008), which tabulate the populations, patient numbers, baseline characteristics, 
interventions, outcomes, data extraction, and assessments of quality for each of the trials. In total, 
87 randomized controlled trials were included (Fig. 1). 
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We noticed that these 87 randomized controlled trials appeared to provide little if any information on 
race/ethnicity and socioeconomic status. To investigate the reporting of race/ethnicity and related 
variables in more detail, we extracted from the 87 trials all available data on race/ethnicity, any socio-
economic variables (e.g., income, place of residence, social class, religion), and demographic 
aspects of the trials (e.g., the number, location and identity of the countries involved) using a standard 
data template (Supplementary Table S4). The data were extracted by one reviewer and checked 
independently by another reviewer. 
 
The 87 randomized controlled trials included in our systematic review (Main et al., 2008; Shepherd et 
al., 2008) comprised 70 on adults (patients aged 12 years or above), 16 on children (aged less than 12), 
and one on both adults and children (Fig. 1). 
 
Of the 87 trials, 23 (26%) stated the race/ethnicity of their participants (Supplementary Table S4). 
This is a significantly lower proportion than would be expected by chance (p< 0.001; binomial 
test), assuming that the authors had an equal likelihood of either reporting or not reporting this 
variable. Of these 23 trials, none explained how race/ethnicity was assigned (whether by self-report or 
investigator classification) and none provided quantitative analyses of race/ethnicity data or discussed 
the possible implications for clinical practice of the racial/ethnic composition of their patient 
populations. The number of randomized controlled trials published per year has increased but the 
proportion reporting race/ethnicity has declined; only 1/14 trials reported race/ethnicity in 2006 (Fig. 
2). Overall, the proportions of trials that reported race/ethnicity (Supplementary Table S4) did not 
differ significantly between studies of adults (21/70) and children (2/16) (p= 0.215; Fisher’s Exact 
test). 
 
Trials that reported race/ethnicity all referred to broad racial/ethnic groups without providing more 
precise information on ancestry, demographics or migration (Supplementary Table S4). None of the 
87 trials reported genetic information for the included populations. Of the 23 trials that reported 
race/ethnicity, six were population-specific, being conducted on patients who were all from 
one broad racial/ethnic group, described as Caucasian (two trials), Indian (two trials), Chinese (one 
trial), or Italian (one trial). The remaining 17 trials reported baseline information for multiple racial/ 
ethnic groups but did not subsequently refer to this information when analyzing and interpreting 
outcomes. Where participants were described as ‘Caucasian’ (10 trials) or ‘Black’ (6 trials), the 
Caucasian participants consistently occupied80% of the study population, whereas the Black 
participants occupied23%. Socioeconomic variables such as household income and place of 
residence were not reported in any of the 87 trials. One trial (number 60 in Supplementary Table S4) 
identified the religion of its participants (Hindu, Muslim, Christian) but did not analyze this 
information. 
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The trials were conducted in at least 50 countries, with the number of countries per trial ranging from 
1 to at least 22 and the number of centres per trial from 1 to at least 246. ‘Centres’ comprised 
hospitals, departments, clinics, physicians, or were not described. Countries were named in 38 trials, 
could be inferred indirectly in a further 26, but were not identified in the remaining 23 trials 
(Supplementary Table S4). 
 
Forty-one (47%) of the trials were multi-national. Of these, 31 stated that country was included as a 
factor or co-variable in statistical analyses of intervention effects, or that the mean data for 
certain clinical outcomes were adjusted for country. However, none of the trials explained these 
analyses or adjustments, and only four mentioned, without any empirical data, that there were no 
significant differences in clinical outcomes between countries, or no country-by-intervention 
interactions (Supplementary Table S4). The majority (38) of the 41 multi-national trials did not 
mention the generalizability of their findings. Authors of three trials (numbers 49, 64 and 81 in 
Supplementary Table S4) stated that their results would be valid in several countries but did not say 
which countries, or for which clinical outcomes. 
 
Of 46 trials that were country-specific, 7 were conducted exclusively in the US (trials 26, 39, 40, 47, 
53, 55, and 79 in Supplementary Table S4) and9 exclusively in the UK (trials1, 9,10,13,19, 21, 27, 30, 
33 in Supplementary Table S4). No other countries had more than four country-specific trials. The 
proportion of trials that reported race/ethnicity differed significantly between those conducted in the 
US (6/7) and UK (1/9) (p= 0.009; Fisher’s Exact test). 
 
Gender was reported at baseline for nearly all (85/87) of the randomized controlled trials. The 
percentage of males ranged from 18% to 93% (mean 50.4%, median 44.5%, mode 43%). However, 
only three of the trials mentioned gender when discussing outcomes (studies 3, 14 and 30 in 
Supplementary Table S4). These referred to a single female withdrawal (study 3), an observation that 
patients with high morning serum cortisol concentrations (>7.0 mmol l
-1
) were all women (study 14), 
and an observation that proportionally more women in one intervention completed the study (study 
30). 
 
Discussion 
 
Our systematic review suggests that the proportion of asthma clinical trials reporting race/ethnicity 
(defined in its broadest sense to include any aspects of race and/or ethnicity) has recently declined. 
This is in contrast to the findings of a review by Brahan and Bauchner (2005) which found an increase 
in the proportion of papers that reported race/ethnicity for paediatric asthma clinical trials. Brahan and 
Bauchner (2005) examined five pre-selected general medical journals for original research articles on 
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paediatric asthma published during 1991–1993 and 2000–2002, not limited to randomized controlled 
trials. However, they included only studies with US researchers and institutions, which are more 
likely than European studies to report race/ethnicity (Sheikh, Panesar, Lasserson, & Netuveli, 2004). 
Our review represents the most comprehensive evaluation carried out so far on the reporting and 
analysis of demographic information in asthma clinical trials, and included studies published in 32 
English language journals without a priori restrictions on the nationality of researchers or type of 
publication (Main et al., 2008; Shepherd et al., 2008). Other reviews have investigated the reporting 
of race/ethnicity for non-asthmatic populations, for example Corbie-Smith, St George, Moody-Ayers, 
and Ransohoff (2003) surveyed three high-impact medical journals and evaluated primary research 
articles published on diabetes, cardiovascular disease, cancer and HIV/AIDS during 1989–2000. 
Walsh and Ross (2003) surveyed three general medical journals and evaluated all original primary 
research articles published during 1999–2000, but limited their evaluation to studies with US 
researchers. Ma, Khan, Kang, Zalunardo, and Palepu (2007) surveyed four high-impact general 
medical journals and evaluated all primary research articles published during 1999–2003 that 
reported race/ethnicity. The two reviews that compared reporting and non-reporting of race/ethnicity 
indicated that 63.5% (Walsh & Ross, 2003) or 59% of publications (Corbie-Smith et al., 2003) had 
reported race/ethnicity during the most recent time periods they surveyed. These are higher 
frequencies of reporting race/ethnicity than we found for the asthma trials, but might not be directly 
comparable with our results due to differences in methodology. 
 
Our systematic review differed from the others, for example, in that it was limited to randomized 
controlled trials but was not restricted to a small subset of pre-specified journals. Our finding that 
none of the asthma clinical trials explained how they assigned race/ethnicity classes to their patients 
(e.g., whether self-reported or researcher-assigned) is broadly consistent with results of a study by 
Shanawani, Dame, Schwartz, and Cook-Deegan (2006) which showed that the majority of medical 
research articles claiming associations among genotype, outcome and race/ethnicity did not 
explain their methods for assigning race or ethnicity.  
 
With such a wealth of historical evidence that asthma diagnosis, morbidity, mortality, treatment, and 
healthcare resource utilisation differ with race/ethnicity and/or socio-economic status (Supplementary 
Tables S1 and S2), together with the numerous reporting recommendations for authors, it seems 
surprising that race/ethnicity and socio-economic variables are rarely reported and analyzed in 
randomized controlled trials. The higher frequency of reporting race/ethnicity in the US than in the 
UK is consistent with findings of a review by Sheikh et al. (2004) and may reflect the fact that 
government-funded research programmes are contractually required in the US, but not in Europe, to 
provide statistics on race/ethnicity. Sheikh et al. (2004) urged European governments and respiratory 
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agencies to consider the US model, but noted that even in the US fewer than 65% of recent asthma 
clinical trials had reported race/ethnicity. 
 
Gender differences in asthma incidence and prevalence have been observed for decades (Almqvist et 
al., 2008), but clinical trials are only now starting to demonstrate the potential importance of gender 
differences in asthma drug efficacy (Johnston et al., 2007; Szefler et al., 2005) and adverse events 
(Ishizuka et al., 2007). Compared to race/ethnicity and socio-economic status, there appears to have 
been less awareness of, or concern about gender differences in asthma (Jensen-Jarolim & Untersmayr, 
2008), which might explain why only three of the 87 randomized controlled trials that we evaluated 
mentioned gender when discussing their outcomes. The gender differences in post-treatment serum 
cortisol concentrations and in the number of patients who completed a study (mentioned in studies 14 
and 30, respectively; Supplementary Table S4), together with the gender differences in asthma 
drug efficacy and adverse events observed in other studies, suggest that gender differences in asthma 
management and outcomes should be considered more critically in future asthma clinical trials. 
 
Limitations and strengths of the review 
 
Our review was conducted during March to September 2006, hence trials published since then are not 
included. However, it is unlikely that reporting of race/ethnicity would have improved since 
then, as we are unaware of any obvious new recommendations or policies to stimulate such a change. 
As our review focuses on asthma, our findings might not reflect the reporting of race/ethnicity for 
other conditions. Our findings are important, however, because of the high prevalence of asthma in 
developed countries and its extensive association with racial/ethnic and other demographic 
inequalities in health outcomes and treatment (Supplementary Tables S1 and S2). 
 
Our review does not rule out the possibility that some authors might have recruited minority 
populations but failed to report the details. We assume that any authors who had gone to the trouble of 
recruiting minority populations would have indicated so. Our findings suggest that there is very 
limited recruitment of minority groups in asthma clinical trials, but it is also clear that trial 
reporting was inadequate, as in the majority (74%) of the trials the racial/ethnic groups that were 
included were not identifiable. 
 
Key strengths of our revieware that it was systematic, impartial, and used the same evidence base 
from the published literature as used by the UK National Institute for Health and Clinical Excellence 
(NICE) to underpin their clinical guidance on asthma management. Our findings provide an insight 
into the availability to NICE and other health agencies of information from the published literature 
on race/ethnicity and other demographic variables. 
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Barriers to reporting and analyzing demographic data 
 
Numerous difficulties in recruiting minority groups to clinical trials have been reported, for example, 
healthcare professionals appear to be unaware of the importance of representational sampling of 
populations (Hussain-Gambles et al., 2004). Researchers may also be discouraged from including 
minority populations by issues of ethics, language difficulties, unclear classification and definition of 
minority groups, health provider attitudes, religious standards and cultural modesty (Hussain-Gambles 
et al., 2004; Sheikh et al., 2004), as well as by institutional racism, other political sensitivities 
(Aldhous, 2002; Witzig, 1996), and arguments that race/ethnicity should not be included in studies 
unless there is a biological, scientific, or sociological reason for doing so (Rivara & Finberg, 2001). 
 
Even if minority populations are recruited to trials, word limits imposed by journals might discourage 
authors from reporting all the available race/ethnicity and socio-economic information, especially as 
authors are already under pressure from CONSORT guidance to report numerous other variables. 
CONSORT guidance does not explicitly require reporting or analysis of race/ethnicity (Moher, 
Schultz, & Altman, 2001), although Sheikh et al. (2004) argued that it should. According to a recent 
survey, only 6% of articles sampled in three US paediatric journals reported race/ethnicity to comply 
with journals’ peer-review requirements (Walsh & Ross, 2003). Online data supplements and 
electronic journal articles are possible options for improving the publication of demographic 
information from clinical trials, provided that editorial and peer-review requirements for the provision 
of such data are enforced. 
 
Generalizing the results – but to which populations and patients? 
 
Under-representation of ethnic minority populations in clinical trials may seriously compromise the 
generalizability of the findings (Cohn, 2006; Hussain-Gambles et al., 2004). According to research 
governance guidance, the body of research evidence must reflect population diversity (Allmark, 2004), 
and this is particularly relevant for asthma, which differs between populations in its prevalence, 
morbidity, mortality, management success, adverse effects, and treatment options. The authors of 
asthma clinical trials that we reviewed appeared to assume that if a clinical trial was conducted 
in several countries or upon several racial/ethnic groups then the effects of the interventions would by 
default be valid in all the countries and racial/ethnic groups. This assumption (an example of 
the ‘ecological fallacy’, or ‘biased sampling’) requires that clinical outcomes were statistically and 
clinically homogeneous among the countries and racial/ethnic groups. However, consistently 
homogeneous outcomes seem rather unlikely, in light of the widely reported differences in asthma 
outcomes between populations (Supplementary Tables S1 and S2). High-profile studies such as 
11 
 
SMART (the Salmeterol Multicenter Asthma Research Trial) have also highlighted how a lack of 
relevant genetic information for trial participants can hinder understanding, interpretation, and 
generalisation of adverse events resulting from asthma management interventions (Lipworth, 2007). 
 
A consistent feature of the papers that we reviewed is that they lacked advice for clinicians about the 
generalizability of their findings, and none provided any guidance to assist clinicians to interpret the 
racial/ethnic applicability of treatment interventions in a patient-centred way. It is unclear, for 
example, whether the fact that Black patients always made up less than 23% of the study 
populations would limit the applicability of the trial findings to an individual Black patient. Despite 
the well documented evidence base for racial/ethnic, socio-economic, and genetic differences in 
asthma, none of the randomized controlled trials provided any formal hypotheses that incorporated 
any of these demographic variables. The trials, therefore, do not link clearly to the demographic 
evidence base and would not contribute to demographic healthcare goals, for example the reduction or 
elimination of demographic disparities in asthma. For the majority of the asthma trials that stated the 
race/ethnicity of their populations (17/23), it is unclear why multiple racial/ethnic groups were 
considered important enough to be included in the trial, yet were not separated when analyzing and 
interpreting outcomes. We assume that the function of the baseline race/ethnicity data in these trials 
was to demonstrate comparability of the racial/ethnic population mix across interventions, rather than 
to investigate effects of the population mix per se. However, to avoid committing the ecological 
fallacy (incorrectly applying aggregate group response data to all individual participants or sub-
groups, such as Black or White patients), prospective trials would either have to be restricted to 
homogeneous populations, sometimes called ‘ethnic specific’ trials, or should include appropriate 
analyses of population sub-groups. The choice of method (ethnic-specific or sub-group analyses) is 
a matter of debate (Cohn, 2006). Ethnic-specific trials have been supported by some authors (Taylor 
& Wright, 2005) but have also been strongly criticized (Cooper & Psaty, 2005) as ‘‘a step backwards’’ 
on account of their limited generalizability, limited prior evidence to justify the selection of a single 
study population, and absence of clinical rationale. Sub-group analyses would need to be defined a 
priori, adequately powered, and based on stratified sampling of the populations in order to detect 
population differences (Yusuf, Wittes, Probstfield, & Tyroler, 1991). To inform the choice of analysis 
approach, it is first necessary to identify whether and where the representation of minorities in 
samples matters, for example whether race/ethnicity is a causal, mediating or nuisance variable 
(Allmark, 2004; Kraemer & Wilson, 2002). As the representation of minorities in clinical trials will 
have costs (more patients need to be recruited to ensure adequate statistical power of sub-group 
analyses), it has been proposed that cost-benefit analysis should be part of the decision making 
process and this should be reported when justifying the selection and analysis of populations in 
clinical trials (Allmark, 2004). 
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There have been extensive recommendations and requirements for the improved representation of 
racial/ethnic minorities in clinical trials, especially in the US (Sheikh et al., 2004), but these have not 
specifically addressed the issues mentioned above about why and how the minority populations 
should be selected, included and analyzed. We suspect that the vagueness of the guidance might be at 
least partly responsible for the limited attention to minority populations in asthma clinical trials. We 
acknowledge that ongoing debates over the merits of ethnic-specific versus sub-group analyses might 
make it difficult to develop very specific guidance on how minority populations should be analyzed in 
clinical trials, but the guidance should at least emphasize the need for transparent justification of 
whichever approaches are used for the selection, inclusion, and analysis of minority populations. Such 
justification should be formulated in clear hypotheses that link to the existing demographic and 
clinical bases of evidence and also to specific healthcare goals. 
 
Regulatory aspects – and contradictions 
 
Extrapolation of the results of clinical trials from a ‘foreign’ geographical region to a ‘new’ region has 
been discussed by the International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH) under the auspices of the European 
Medicines Agency (EMEA) (European Medicines Agency, 1998). The ICH advises that for 
registration of medicines in the three ICH regions (Europe, the US, and Japan), it is critical to evaluate 
data in the major ‘racial’ groups most relevant to these regions, namely Caucasian, Black and Asian. 
However, this guidance appears to have ignored the criticism that such broad racial/ethnic groups lack 
biological relevance. Recent guidance from EMEA (European Medicines Agency, 2006) mentions 
that ‘race’ should usually be reported in clinical studies and, ideally, analyzed quantitatively. 
However, ‘race’, unlike ‘ethnicity’ (European Medicines Agency, 1998), is not explicitly defined by 
EMEA. The guidance (European Medicines Agency, 1996) also states that multi-centre studies should 
report results for individual centres and the comparability of centres should be assessed if possible, 
although our findings provide no evidence that such information from randomized controlled trials 
has reached the peer-reviewed literature. The European guidance seems to suffer not only from 
inconsistency with recommendations in the literature but also exhibits the problem that we refer to 
above – that it may be too vague to elicit specific action in terms of establishing how and why 
minorities should be included and analyzed in clinical trials.  
 
An important leap: from clinical study reports to the public domain 
 
Health regulatory agencies require more detailed information on clinical studies than would be 
feasible to report in published articles of the type included in our systematic review. For example, 
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EMEA require detailed data for each of the patients involved in a clinical study (European Medicines 
Agency, 1996), and regulatory dossiers supplied by drug manufacturers may contain thousands 
of pages of information. Our review may, therefore, have underrepresented the extent to which data 
on race/ethnicity and socio-economic variables have been collected and analyzed. Nevertheless, the 
published literature reflects the majority of data accessible to clinicians, patients and researchers, 
whereas unpublished data from clinical trials are usually considered commercially confidential and 
effectively inaccessible. Strategic plans by the US National Institutes of Health (National Institutes of 
Health, 2004) and others to increase the representation of ‘minority and ethnic populations’ in clinical 
trials are unlikely to assist researchers and policymakers if the data they stimulate remain confined to 
clinical study reports and regulatory dossiers. Our review identifies a clear need to improve the 
transfer of such information into the public domain, underlining recommendations made by the World 
Health Organization that research findings ‘‘should not only be accessible to decision-makers but also 
communicated in ways that effectively inform policy, public health and health care decision-making’’ 
(World Health Organization, 2005). 
 
Recommendations 
 
Guidance on the conduct of asthma clinical trials should encourage more critical consideration and 
clearer reporting of how and why populations are selected and analyzed. Current guidance that merely 
recommends or requires that minorities are included in clinical trials, without requiring an explanation 
of how or why is unlikely to result in the generation of evidence relevant to demographic 
healthcare goals such as reducing or eliminating healthcare disparities in asthma. There is also a need 
for more critical consideration of the generalizability of clinical trial findings. Ideally, population 
analyses should be based on clearly specified hypotheses that link both to the existing demographic 
and clinical evidence and to demographic and clinical healthcare goals. Guidance should also 
stress the need for more precise reporting of demographic characteristics and genetic information, in 
order to reduce the subjectivity of describing and interpreting population classifications; to distance 
research trials from political sensitivities associated with race and ethnicity and from debates over the 
relative importance of genetic and environmental factors; and to facilitate a clearer understanding 
of the generalizability of trial findings. 
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Figure legends 
 
Figure 1. QUOROM chart summarizing the provenance of published papers 
included in the systematic review. 
 
Figure 2. Temporal distribution of randomized controlled trials (RCTs) 
included in the systematic review. 
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